| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3352767a568d0beebdfb74387361328 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-1307
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-1384
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-603 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-545 |
| filingDate |
2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ba14bcf57cbe6f96aee0d20064c1d7b |
| publicationDate |
2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019136200-A1 |
| titleOfInvention |
Cellular Reprogramming Utilizing mRNA |
| abstract |
Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019241569-A1 |
| priorityDate |
2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |